LISATA THERAPEUTICS, INC. — Director's Dealing 2015

Jul 2, 2015

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Caladrius Biosciences, Inc. (CLBS)
CIK: 0000320017
Period of Report: 2015-06-30

Reporting Person: Talamo Joseph (Chief Accounting Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2015-06-30	Common Stock, $0.001 par value	A	1574	$1.5895	Acquired	32413	Direct

Footnotes

F1: Shares purchased pursuant to Caladrius Biosciences, Inc.'s 2012 Employee Stock Purchase Plan for the period ended June 30, 2015.